IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we have initiated a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with solid and hematologic malignancies, for which we have recently initiated a Phase 1 clinical trial. Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Location: United States, California, Mountain View
Employees: 51-200
Total raised: $102M
Founded date: 2010
Investors 1
Date | Name | Website |
- | Vivo Capit... | vivocapita... |
Funding Rounds 1
Date | Series | Amount | Investors |
08.07.2019 | Series C | $102M | - |
Mentions in press and media 8
Date | Title | Description | Source |
07.03.2024 | IGM Biosciences Announces Fourth Quarter and Full Year 2023 ... | - | globenewsw... |
11.10.2021 | The first-ever COVID-19 pill may be just weeks away. A handf... | A man holds a capsule. Photographer, Basak Gurbuz Derman/Getty Images Treating COVID-19 could be sim... | businessin... |
30.07.2021 | Top Gilead cancer researcher jumps to a startup as Dan Ch... | Chris Takimoto Chris Takimoto, the former CMO at Forty Seven who completed a stint as SVP of... | endpts.com... |
09.07.2019 | IGM Biosciences grabs $102M to push bispecific into the clin... | IGM Biosciences picked up $102 million in series C financing to work on its pipeline of cancer drugs... | fiercebiot... |
09.07.2019 | IGM Biosciences grabs $102M to push bispecific into the clin... | IGM Biosciences picked up $102 million in series C financing to work on its pipeline of cancer drugs... | fiercebiot... |
09.07.2019 | Three Cancer Drug Developers Raise Big Rounds, Securing Over... | 7 Shares Email Facebook Twitter LinkedIn In medical-related funding news, three companies focused on... | news.crunc... |
09.07.2019 | IGM Biosciences Inks $102M Series C | MOUNTAIN VIEW, CA, IGM Biosciences today announced the closing of its $102 million Series C financ... | vcnewsdail... |
08.07.2019 | IGM Biosciences Raises $102M in Series C Financing | IGM Biosciences, Inc., a Mountain View, Calif.-based biotechnology company and a global leader in th... | finsmes.co... |